The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects

  • Hui H
  • Farilla L
  • Merkel P
 et al. 
  • 25


    Mendeley users who have this article in their library.
  • 58


    Citations of this article.


The incretin hormone glucagon-like peptide-1 (GLP-1) is capable of ameliorating glucose-dependent insulin secretion in subjects with diabetes. However, its very short half-life (1.5-5 min) in plasma represents a major limitation for its use in the clinical setting. The present study was designed to characterize the duration of the effect of GLP-1 in the Zucker diabetic fatty (ZDF) rat. ZDF rats were subjected to a 48 h infusion of human GLP-1 (30 pmol/kg per min), followed by an i.p. glucose tolerance test (IPGTT) (1 g/kg body weight), 2 h after removing the infusion pump. At 15 min from the beginning of the test, GLP-1-treated animals had lower plasma glucose levels (442+/-38 mg/dl) than saline-infused controls (583+/-63 mg/dl, P

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Hongxiang Hui

  • Loredana Farilla

  • Patricia Merkel

  • Riccardo Perfetti

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free